Latest Insider Transactions at Sarepta Therapeutics, Inc. (SRPT)
This section provides a real-time view of insider transactions for Sarepta Therapeutics, Inc. (SRPT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Sarepta Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Sarepta Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 03
2021
|
Louise Rodino Klapac President, R&D and Tech Ops |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+40.36%
|
-
|
|
Mar 03
2021
|
Hans Lennart Rudolf Wigzell |
BUY
Grant, award, or other acquisition
|
Direct |
2,726
+14.17%
|
-
|
|
Dec 31
2020
|
Douglas S Ingram Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
37,144
-9.4%
|
$6,314,480
$170.49 P/Share
|
|
Dec 11
2020
|
Joseph Bratica Principal Financial Officer |
SELL
Open market or private sale
|
Direct |
1,115
-12.05%
|
$183,975
$165.0 P/Share
|
|
Dec 11
2020
|
Joseph Bratica Principal Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,115
+10.75%
|
$79,165
$71.45 P/Share
|
|
Dec 10
2020
|
Mary Ann Gray Director |
BUY
Exercise of conversion of derivative security
|
Direct |
967
+14.48%
|
-
|
|
Dec 08
2020
|
Joseph Bratica Principal Financial Officer |
SELL
Open market or private sale
|
Direct |
1,125
-12.14%
|
$180,000
$160.0 P/Share
|
|
Dec 08
2020
|
Joseph Bratica Principal Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,125
+10.83%
|
$32,625
$29.6 P/Share
|